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Cellular Antigen Stimulation Test (CAST) as a Novel,
Affordable Laboratory Technique to Assess Potential
Hypersensitivity to All Available Antiretroviral Com-
pounds
R. Manfredi1,∗, S. Sabbatani1, S. Bergonzi2
1 Department of Infectious Diseases, University of Bologna,
S. Orsola Hospital, Bologna, Italy
2 Department of Pathology, ‘Maggiore’ General Hospital,
Bologna, Italy
Introduction: Recently,novel allergometric techniques
allow to test inhalants,food,and also drugs by speciﬁc
in vitro assays. A ﬂow cytometry technique based on
the search of sulphidoleukotrienes LCT4, LTD4 and LTE4
released by basophils stimulated in vitro by IL-3 in
presence of the examined antigens (cellular antigen stim-
ulation test,or CAST), has a 80—90% sensitivity-speciﬁcity
rate,and becomes particularly useful when prick tests are
not applicable, and allergic reactions are not mediated
by allergen-speciﬁc IgE immunoglobulins.Methods-Results:
During the past three years, 13 HIV-infected subjects (eight
females and ﬁve males, aged 37—52 years),underwent a
standardized, speciﬁc in vitro cellular antigen stimulation
test (CAST),due to serious cutaneous (six cases),systemic
(two patients), and combined cutaneous-systemic hyper-
sensitivity reactions (ﬁve subjects),apparently not elicited
by the introduction of abacavir and nevirapine (which are
the antiretroviral agents burdened by the greatest fre-
quency of expected early allergic reactions,mediated by
already recognized pathogenetic mechanisms). Based on the
results of CAST testing, an allergic intolerance to ritonavir
(six cases), lopinavir,nelﬁnavir, and didanosine (three cases
each), saquinavir and lamivudine (two cases), and fosam-
prenavir,zidovudine, zalcitabine, stavudine, and efavirenz
(one case each), was documented: in 10 cases out of 13
(76.9.5%) multiple intolerances were detected. A perfect
relationship was documented between the results of CAST
testing and the panel of combined antiretroviral compounds
recently experienced by each allergic patient,and a CAST-
based elimination of in vitro allergenic molecules allowed a
rapid introduction of another effective antiretroviral com-
bination.
Conclusions: Adverse events to antiretroviral drugs are
quite frequent among HIV-infected patients, compared
with the general population. Further,controlled studies are
needed to implement in vitro allergometric testing in
patients treated for HIV infection,who are exposed to unpre-
dictable drug intolerance reactions. In fact,HIV-infected
subjects may suffer from frequent allergic drug reactions
which may be difﬁcult to be systematically recognized (due
to the frequent,multiple concurrent pharmacotherapy, and
the combined antiretroviral therapy itself).
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HIV Genotypes and Patterns of Drug Resistance in Patients
Failing HAART in a University Hospital Clinic
G. Revathi ∗, M. Bholla, P. Wangai, R. Harania, P. Ojwang
The Aga Khan University Hospital, Nairobi, Kenya
Background: HAART strategies yield excellent results in
drug na¨ıve patients starting ﬁrst-line treatment. Yet, data
from clinical cohorts indicate drug resistance emerging as
a consequence of toxicity, drug interactions or adherence
problems leading to sub-optimal serum drug concentrations.
The Aga Khan University Hospital, Nairobi, has compre-
hensive HIV care services since 2003 at the one stop clinic.
About 500 patients are on current follow-up by standard
international protocols.
Methods: Over one year, 38 patients failed ART and
were referred to the laboratory for resistance testing per-
formed by population sequencing technique using VIRASEQ
(Abbott) by manufacturer’s protocol. All clinical details
were recorded during sample collection.
Results: All patients belonged to a high socioeconomic
group with corporate health insurance cover and claimed
excellent drug adherence.
Patient age ranged from 6 to 57 years with a median
of 38 years. CD4 counts ranged from 12 to 450 with a
median of 135. Viral loads ranged from 2100 to 13 mil-
lion with a median of 140,000. 82% (31/38) of patients had
multiple hospital admissions indicating 2 to 5 episodes of
opportunistic infections of which TB (14 patients), PCP (11
patients), Cryptococcosis (10 patients) and Salmonellosis (8
patients) were most common. 4 patients had 3 simultane-
ous opportunistic infections. 6 patients had 2 simultaneous
opportunistic infections. Only 8 patients were on second-line
HAART which included boosted PI. 9 patients used ARVs for
over 10 years. A, D and CRFO1 were predominant subtypes.
Major NRTI/NNRTI mutations were seen in 80% of patients
while major PI mutations were seen in 8% of patients. High-
level resistance was seen to Tenofovir in 8% of patients,
Nevirapine, Efaverenz, 3TC & FTC in 80% of patients and
AZT in 29% of patients.
Conclusions: In the long run, high-level multiple resis-
tance is inevitable in patients on HAART, with serious
implications for national ARV programs and prophylactic reg-
imens.
doi:10.1016/j.ijid.2008.05.509
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Multi-Pronged Strategy Greatly Enhances Enrollment of
HIV Positive Children Into HIV Care and Treatment: Expe-
rience from Uganda
E.M. Namagala ∗, H. Balidawa, E. Madraa
STD/AIDS Control Program, Ministry of Health, Kampala,
Uganda
Background: Although Uganda had successfully rolled out
Antiretroviral therapy (ART) in HIV-infected adults, enroll-
ment of children aged less than 15 years onto ART had
generally been very slow. However, the implementation of a
multi-pronged strategy for scaling-up pediatric HIV care has
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greatly improved enrollment of children into HIV care and
ART over the past two years.
Methods: The activities for the multi-pronged strategy
were developed by the national Pediatric ART Committee
that is comprised of major stakeholders in pediatric HIV care
and they include:
- Development of a national strategy for scaling up pediatric
HIV care including a capacity-building plan for pediatric
HIV care and treatment.
- Advocacy, Community mobilization and education on pedi-
atric HIV care, treatment and prevention
- Establishment of a nationwide system for Early Infant HIV
diagnosis using DNA PCR
- Strengthening of linkages between PMTCT services with
HIV care clinics, Postnatal clinics and Maternal and Child
Health services
- Countrywide refresher training in pediatric HIV care
including Child counselling with follow-up of trained
health workers
- Training of specialized pediatric HIV counselors
- Provision of family-centred, comprehensive pediatric HIV
services that include community follow-up and nutritional
support
- Establishment of regional supervision and mentoring in
pediatric HIV care
- Use of pediatric dosing wheels and job aides
- Use of simple pediatric ART formulations
Results: The number of children on ART has risen from
5000 by end of December 2005 to 12,000 by the end Decem-
ber 2007. The number of health facilities providing ART to
children less than 15 years of age has increased from 47 sites
to 174 sites out of the total 303 ART sites in the same period.
Conclusion: Scaling-up pediatric HIV care requires a
comprehensive and multi-pronged strategy with innovative
activities that involve all stakeholders in pediatric HIV care.
doi:10.1016/j.ijid.2008.05.510
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A Role for Chlamydia pneumoniae in Inducing IL-10, IL-
13, IL-18 and the Chemokines CCL3-alpha, CCL3-beta and
CCL5 in Atherosclerotic Patients
M. Bakhiet ∗, A. Al-Zaki, S. Taha
Arabian Gulf University, Manama, Bahrain
The present work explored the spontaneous induction of
the inﬂammatory cytokine Interleukin (IL)-18 and the anti-
inﬂammatory cytokine IL-10 and IL-13, and the chemokines
CCL3 alpha and beta (macrophage- inﬂammatory protein-
1alpha and beta, CCR1/5 ligand), (CCL5, regulated upon
activation, normal T cell expressed and secreted (RANTES,
CCR5 ligand) in atherosclerotic patients. In addition, the
effects of the chlamydial antigen HSP60 and LPS on the
induction of these mediators were examined. Intracellu-
lar detection of cytokines and chemokines was assessed
by immunohistochemistry. The results of these experiments
showed signiﬁcantly high levels of spontaneously produced
IL-18, IL-13 and IL-10 in patients compared to healthy con-
trols. Cells stimulated with CHSP60 showed signiﬁcantly high
production of IL-18, but not IL-13 or IL-10. However, LPS
stimulation resulted in increased levels of IL-18 and IL-10,
but not IL-13 compared to non-stimulated cells. The exam-
ined chemokines were detected at signiﬁcantly high levels
on atherosclerotic patients compared to healthy controls.
Stimulation with HSP60 and LPS showed increased levels
of CCL3alpha, CCL3beta and CCL5 in patients compared to
healthy controls. Thus, we demonstrate for the ﬁrst time
the induction of these inﬂammatory and anti-inﬂammatory
mediators in atherosclerotic patients and that chlamydial
antigens play a role in the immunopathological events in this
disease by generating more inﬂammatory mediators rather
than anti-inﬂammatory response.
doi:10.1016/j.ijid.2008.05.511
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Cloning of a Cysteine Protease of Avian Staphylococcus
aureus and its Expression in E. coli
Y. Kazi
Shah Abdul Latif University, Khairpur, Pakistan
Background: Staphylococcus aureus infections are one of
the major causes of economic loss in poultry industry and
cysteine protease may be one of the major virulence factors
of avian S.aureus. All avian species appear to be susceptible
to staphylococcosis, which is common worldwide wherever
poultry are reared. There are zoonotic risks to humans that
S. aureus can cause food poisoning. In order to provide a
rational research basis for detection of pathogenicity of S.
aureus and study on the virulence factors and expression
system, this study on cysteine protease of avian S. aureus
was conducted.
Methods: The fragment of protease gene of S. aureus
from a standard avian strain was ampliﬁed by PCR and
cloned into prokaryotic expression plasmid vector pET33b+
with restriction endonuclease to construct recombinant pET-
protease, which was veriﬁed, by restriction endonuclease
and DNA sequencing. The recombinant plasmid was trans-
formed into E. coli BL21/DE3 to express the protease gene.
The production of protease was induced by IPTG. Construc-
tion of recombinant plasmid pET33b+ with the protease gene
inserted downstream of an N-terminal his-tag and transfor-
mation into heterologous expression host E.coli BL21/DE3
resulted in the strain BL21/DE3 pET33b+. The presence of
protease gene in recombinant cells was conﬁrmed by colony
PCR and restriction digestion with appropriate enzymes and
sequencing.
Clones of this strain were tested for production
of protease before and after induction with IPTG and
immunoblotting with pooled polyclonal sera of chicken
known to be infected with S. aureus and monoclonal anti
his-tag antibodies.
Results: The result showed protease DNA fragment was
proved correct through digestion with restriction endonucle-
ase and DNA sequencing. Its sequence was 99% homologous
to that published in Gene Bank (gi:19570341). A 36 and
40 kDa fusion protein, which was induced by IPTG, was
detected by SDS-PAGE. In immunoblots, the recombinant
